The Sumitomo Dainippon-Roivant Alliance will be wholly owned by Sumitomo, which is also taking control of five companies - and potentially six more - from Ramaswamy's Vant family of firms.
Billion-dollar private venture capital rounds are apparently now a "thing." Roivant sealed the deal on Wednesday, following a multi-year trend towards bigger investment rounds in the life sciences.
Closing cancer health equity gaps require medical breakthroughs made possible by new funding approaches.
Myovant is making the most of its $218M IPO. The women's health company has launched two international Phase 3 trials for its lead compound, relugolix, with another three planned for the first half of 2017 — just in time for its one-year anniversary.
Roivant's search for overlooked and underpriced compounds continues, as it builds out more subsidiaries and completes enrollment on its first Phase 3 trial.
Myovant Sciences has orchestrated the largest biotech IPO of the year thus far, five months after their launch and with just nine employees on payroll.